Myofascial Trigger PointsNCT07347028
Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Knee Osteoarthritis(OA)
A study testing MTrPs Injection and Intra-articular(IA) Injection in people with Myofascial Trigger Points and Migraine, run by Beijing Tiantan Hospital at 1 site in China.
Trial summary
Chronic musculoskeletal pain (CMP) is a common disease in China, with a high incidence among the elderly, and has a significant impact on patients' quality of life. Knee osteoarthritis is a common type of CMP. Read more about this study
- Who is it for?
- Ages 45 years and older
- Conditions the study is for
- Myofascial Trigger Points, Migraine, Cervicogenic Headache
- What is being tested?
- MTrPs Injection and Intra-articular(IA) Injection
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 238 participants
- Where
- 1 siteChina
- Study dates
- 1 Oct 2025to 1 Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of knee osteoarthritis with radiographic evidence of osteoarthritis (Kellgren-Lawrence grade 1-4) confirmed by at least two orthopedic surgeons, pain specialists, or general practitioners, with physical examination confirming at least one myofascial trigger point;
- Disease duration exceeding 3 months;
- Age ≥ 45 years;
- Numerical Rating Scale (NRS) score ≥ 3 points despite prior conservative pharmacological treatment;
- Signed informed consent form.
Who cannot join
- History of allergy to trial medications such as corticosteroids;
- Alcohol abuse; long-term use of opioids (exceeding 2 weeks or more than 3 days per week for over 1 month); suspected use of sedative or analgesic medications; patients on long-term steroid therapy;
- Severe neurological disorders, significant hepatic or renal dysfunction, heart failure, coagulation abnormalities, gastric ulcer, diabetes, inflammatory rheumatic diseases, etc.;
- Intra-articular injection within the past 6 months or planned joint replacement surgery;
- Inability to use pain assessment scales;
- Presence of local or systemic infection;
- Pregnant or lactating patients.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Beijing Tiantan Hospital
Beijing, Beijing Municipality, 100070
Fang Luo, +86 13611326978, 13611326978@163.com
About this study
Official title: Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Chronic Musculoskeletal Pain(CMP), Chronic Migraine and Cervicogenic Headache
Chronic musculoskeletal pain (CMP) is a common disease in China, with a high incidence among the elderly, and has a significant impact on patients' quality of life. Knee osteoarthritis is a common type of CMP. Currently, both domestic and international studies have confirmed that glucocorticoid injection at myofascial trigger points(MTrPs) can alleviate patients' pain symptoms. MTrPs injection is safe and easy to operate, and can improve the clinical management efficiency of patients with knee osteoarthritis. Therefore, we designed a prospective, randomized controlled, blinded outcome, non-inferiority study to compare the long-term clinical efficacy of glucocorticoid injection at myofascial trigger points and complex intra-articular injection in treating knee osteoarthritis. Patients will be randomly divided into two groups and receive either glucocorticoid injection at MTrPs or joint cavities. After treatment, patients will be followed up for 2 years. Their NRS scores, WOMAC scores, Patient Global Impression of Change(PGIC) scale, and adverse reactions will be recorded at 2 weeks, 4 weeks, 8 weeks, 12 weeks, and 24 weeks. If the results indicate that the clinical efficacy of myofascial trigger point injection for knee osteoarthritis is not inferior to that of injection at intra-articular injection, it will provide a safe and simple treatment option that is easy to promote for patients who do not respond to conservative treatment.
- Being tested
- MTrPs Injection, Intra-articular(IA) Injection
- Medical subject headings
- Migraine Disorders, Post-Traumatic Headache
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MTrPs InjectionProcedure or surgery
Each MTrP is identified by palpation, no more than 10 of the most painful MTrPS are selected for injection. Prior to treatment, the assessed MTrPs are marked with a permanent marker. Each MTrP receiving 1 mL of injection volume. The injection solution is prepared with normal saline, lidocaine and 0.5 ml TA (40mg/ml) to the volume required for treatment. A 25-gauge needle is used to inject perpendicular to the skin surface at the selected MTrPs, with the solution administered as a single bolus into each MTrP within 10 seconds.
Intra-articular(IA) InjectionProcedure or surgery
Patients in the IA injection group will receive an IA knee injection via an anterolateral approach. The injection solution is prepared using 0.5 mL of 1% lidocaine and 0.5 mL of TA (40 mg/mL). The IA injection will be performed under ultrasound guidance to guarantee and reduce the incidence of bleeding or infection.
| Study group | Role | What they receive |
|---|---|---|
| Joint cavity injection group | Active comparator | Joint cavity injection with triamcinolone acetonide Receives: Procedure: Intra-articular(IA) Injection |
| MTrPs injection group | Experimental | MTrPs injection with triamcinolone acetonide. Receives: Procedure: MTrPs Injection |
What is being measured
The primary outcome is the main question the study is designed to answer.
the change from baseline in the WOMAC score
The WOMAC assesses pain, stiffness, and physical function, with higher scores indicating more severe symptoms and greater functional limitation.
Measured: at the 4-weeks
Secondary outcomes (8)
the change from baseline in the WOMAC scores
The WOMAC(Western Ontario and McMaster Universities Osteoarthritis Index) is a standardized instrument specifically designed to assess symptoms and function in patients with knee/hip osteoarthritis. It comprises three dimensions with a total of 24 items: pain (5 items), stiffness (2 items), and physical function in daily activities (17 items). It utilizes a Likert scale (0-4 points, 0 = no symptoms), with a total score range of 0-96 points (or standardized to 0-100 points). Higher scores indicate greater functional impairment.
Measured: at the weeks 2, 4, 8, 12, and 24
NRS pain scores
The pain intensity of the knee will be measured based on NRS, where 0 represents no pain and 10 represents worst pain imaginable.
Measured: At the weeks 2, 4, 8, 12 and 24
The Patient Global Impression of Change (PGIC) scale
The Patient Global Impression of Change (PGIC) scale is a patient-rated instrument used to evaluate overall change in status following treatment. It employs a 7-point Likert scale (1 = "very much worse" to 7 = "very much improved"), focusing on the patient's subjective perception of symptoms, function, and quality of life. The evaluation criterion defines a score of 5 or higher as indicative of "improvement" (mild/moderate/marked), a score of 4 as "no change," and scores of 3 or below as "worsening."
Measured: at the weeks 2, 4, 8, 12, and 24
Knee performance
including nee flexion, extension deficit, maximal flexion, and total range of motion
Measured: at baseline and at the weeks 4, 12, and 24
Myofascial outcomes
including the number of active myofascial trigger points, pressure pain thresholds at predefined trigger-point sites, pain intensity during standardized palpation, and reproduction of the participant's usual knee pain
Measured: at baseline and at the weeks 4, 12, and 24
Health-related quality of life
Health-related quality of life will be assessed using the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L).
Measured: at baseline and the weeks 4, 12, and 24
Rescue analgesic consumption, additional knee-related treatments, unscheduled medical visits, and clinically relevant pain recurrence
Rescue analgesic consumption, additional knee-related treatments, unscheduled medical visits, and clinically relevant pain recurrence
Measured: throughout the 24-week follow-up period
Adverse Reactions
Any systemic adverse reactions related to corticosteroids such as hyperglycemic reactions, infection at the puncture site, and intra-articular infection.
Measured: throughout the 24-week follow-up period.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jan 2026
- Study start1 Oct 2025
- Primary completion1 Dec 2026 (estimated)
- Study completion1 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Myofascial Trigger PointsStudies of the same condition, open and under way.
- More trials run by Beijing Tiantan HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 238 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Beijing Tiantan Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Renmin Hospital of Wuhan University, The Second Affiliated Hospital of Harbin Medical University, The First Affiliated Hospital of Nanchang University, Beijing Aerospace General Hospital, Beijing Rehabilitation Hospital, Yangyuan Youyi Hospital
- Responsible party
- Principal investigator, Fang Luo, Beijing Tiantan Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07347028
- Sponsor's protocol ID
- KY2025-317-02-01
- Status last verified
- Oct 2026
- First submitted
- 16 Dec 2025
- Last updated
- 8 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 8 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Chronic Musculoskeletal Pain(CMP), Chronic Migraine and Cervicogenic Headache
- ClinicalTrials.gov ID
- NCT07347028
- Acronym / sponsor ID
- KY2025-317-02-01
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 238 participants (estimated)
- Lead sponsor
- Beijing Tiantan HospitalUniversity, hospital or other
- Collaborators
- Renmin Hospital of Wuhan University, The Second Affiliated Hospital of Harbin Medical University, The First Affiliated Hospital of Nanchang University, Beijing Aerospace General Hospital, Beijing Rehabilitation Hospital, Yangyuan Youyi Hospital
- Study start
- 1 Oct 2025 (actual)
- Primary completion
- 1 Dec 2026 (estimated)
- Study completion
- 1 Jan 2027 (estimated)
- First posted
- 16 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Chronic musculoskeletal pain (CMP) is a common disease in China, with a high incidence among the elderly, and has a significant impact on patients' quality of life. Knee osteoarthritis is a common type of CMP. Currently, both domestic and international studies have confirmed that glucocorticoid injection at myofascial trigger points(MTrPs) can alleviate patients' pain symptoms. MTrPs injection is safe and easy to operate, and can improve the clinical management efficiency of patients with knee osteoarthritis. Therefore, we designed a prospective, randomized controlled, blinded outcome, non-inferiority study to compare the long-term clinical efficacy of glucocorticoid injection at myofascial trigger points and complex intra-articular injection in treating knee osteoarthritis. Patients will be randomly divided into two groups and receive either glucocorticoid injection at MTrPs or joint cavities. After treatment, patients will be followed up for 2 years. Their NRS scores, WOMAC scores, Patient Global Impression of Change(PGIC) scale, and adverse reactions will be recorded at 2 weeks, 4 weeks, 8 weeks, 12 weeks, and 24 weeks. If the results indicate that the clinical efficacy of myofascial trigger point injection for knee osteoarthritis is not inferior to that of injection at intra-articular injection, it will provide a safe and simple treatment option that is easy to promote for patients who do not respond to conservative treatment.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Joint cavity injection group | Active comparator | Procedure: Intra-articular(IA) InjectionJoint cavity injection with triamcinolone acetonide |
| MTrPs injection group | Experimental | Procedure: MTrPs InjectionMTrPs injection with triamcinolone acetonide. |
Who may qualify
- Ages
- 45 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Diagnosis of knee osteoarthritis with radiographic evidence of osteoarthritis (Kellgren-Lawrence grade 1-4) confirmed by at least two orthopedic surgeons, pain specialists, or general practitioners, with physical examination confirming at least one myofascial trigger point;
- Disease duration exceeding 3 months;
- Age ≥ 45 years;
- Numerical Rating Scale (NRS) score ≥ 3 points despite prior conservative pharmacological treatment;
- Signed informed consent form.
Key exclusion criteria (7 listed)
- History of allergy to trial medications such as corticosteroids;
- Alcohol abuse; long-term use of opioids (exceeding 2 weeks or more than 3 days per week for over 1 month); suspected use of sedative or analgesic medications; patients on long-term steroid therapy;
- Severe neurological disorders, significant hepatic or renal dysfunction, heart failure, coagulation abnormalities, gastric ulcer, diabetes, inflammatory rheumatic diseases, etc.;
- Intra-articular injection within the past 6 months or planned joint replacement surgery;
- Inability to use pain assessment scales;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MTrPs InjectionEach MTrP is identified by palpation, no more than 10 of the most painful MTrPS are selected for injection. Prior to treatment, the assessed MTrPs are marked with a permanent marker. Each MTrP receiving 1 mL of injection volume. The injection solution is prepared with normal saline, lidocaine and 0.5 ml TA (40mg/ml) to the volume required for treatment. A 25-gauge needle is used to inject perpendicular to the skin surface at the selected MTrPs, with the solution administered as a single bolus into each MTrP within 10 seconds. | Procedure or surgery | MTrPs injection group |
| Intra-articular(IA) InjectionPatients in the IA injection group will receive an IA knee injection via an anterolateral approach. The injection solution is prepared using 0.5 mL of 1% lidocaine and 0.5 mL of TA (40 mg/mL). The IA injection will be performed under ultrasound guidance to guarantee and reduce the incidence of bleeding or infection. | Procedure or surgery | Joint cavity injection group |
Primary outcome
the change from baseline in the WOMAC score
Time frame: at the 4-weeks
The WOMAC assesses pain, stiffness, and physical function, with higher scores indicating more severe symptoms and greater functional limitation.
8 secondary outcomes
the change from baseline in the WOMAC scores
Time frame: at the weeks 2, 4, 8, 12, and 24
NRS pain scores
Time frame: At the weeks 2, 4, 8, 12 and 24
The Patient Global Impression of Change (PGIC) scale
Time frame: at the weeks 2, 4, 8, 12, and 24
Knee performance
Time frame: at baseline and at the weeks 4, 12, and 24
Myofascial outcomes
Time frame: at baseline and at the weeks 4, 12, and 24
Health-related quality of life
Time frame: at baseline and the weeks 4, 12, and 24
Rescue analgesic consumption, additional knee-related treatments, unscheduled medical visits, and clinically relevant pain recurrence
Time frame: throughout the 24-week follow-up period
Adverse Reactions
Time frame: throughout the 24-week follow-up period.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Oct 2026.
- Individual participant dataSharing planned: Yes
Related trials for Myofascial Trigger Points
Not yet recruiting
Effects of IASTM, Deep Friction Massage, and Sham Instrument-Assisted Soft Tissue Mobilization on Electromyographical Activation, Pain and Function in Non-Specific Low Back Pain
Low Back Pain, Trigger Point Pain, Myofascial
Recruiting
Comparing Myofascial Exercise and Trigger Point Therapy for Non-Specific Low Back Pain
Non-specific Low Back Pain
Not yet recruiting
Trigger Point Injection and Myofascial Release for Cervicogenic Headache
Cervicogenic Headache
Recruiting
Myo-Electrical and Nerve Root Function Response to Focused Extracorpeal Shock Wave in Cervical Radiculopathy
Cervical Radiculopathy
Recruiting
Evaluation of the Effect of Adding Sodium Bicarbonate to Lidocaine in the Treatment of Myofascial Pain Syndrome
Myofacial Pain, Myofacial Pain Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing MTrPs Injection and Intra-articular(IA) Injection in people with Myofascial Trigger Points and Migraine, run by Beijing Tiantan Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Fang Luo (+86 13611326978, 13611326978@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
the change from baseline in the WOMAC score (time frame: at the 4-weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Oct 2026.